Amylin Announces New Clinical Data From EUREXA Study - Quick Facts

6/9/2012 8:53 AM ET

Amylin Pharmaceuticals, Inc. (AMLN: Quote) announced new clinical data from the European Exenatide or EUREXA study that showed treatment with BYETTA injection resulted in greater glycemic durability and overall glycemic control than Amaryl in patients with type 2 diabetes uncontrolled on metformin alone.

The company also noted that patients treated with BYETTA have experienced reductions in body weight and fewer hypoglycemic events.

The company said these clinical study findings are being presented at the 2012 ADA/The Lancet Symposium at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.

Click here to receive FREE breaking news email alerts for Amylin Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 69 Articles

Editors Pick

BoJ Keeps Easing Plan Intact; Upgrades Economic View

The Bank of Japan on Wednesday decided to keep its ultra-loose monetary policy unchanged, as expected, suggesting that the bank is moving cautiously amid concerns over the recent turmoil in the bond market. The policy board said the bank will conduct money market operations so that the monetary base will increase at an annual pace of about JPY 60-70 trillion.

Australia Consumer Morale Falls Sharply On Budget

Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012.

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.